<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>18620653</identifier>
<setSpec>0014-2565</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>de La Tassa, J Moris</dc:author>
<dc:author>Arias Miranda, M I</dc:author>
<dc:author>González García, M E</dc:author>
<dc:author>Fernández Alvarez, C</dc:author>
<dc:author>González Huerta, A J</dc:author>
<dc:author>González Rodríguez, A P</dc:author>
<dc:author>Robles Marinas, V</dc:author>
<dc:author>García Casas, J</dc:author>
<dc:author>Fernández García, J</dc:author>
<dc:description xml:lang="en">INTRODUCTION How to identify monoclonal gammopathies of undeterminated significance (MGUS) at risk for progression has been studied for the last years. AIMS To study the incidence of MGUS in a region with 300,000 inhabitants and factors which associate with a) monoclonal gammopathy disappearance (transient MGUS) b) evolution to malignant gammopathy. METHODS Study of 618 MGUS. RESULTS Incidence: 30/40 new cases a year with increase to 70 cases a years in the latest years of study. Age and gender: 71,4 y (32-100), male/female ratio 1.4. Associated pathology: infection 328, heart diseases 249, rheumatic diseases 211, liver diseases 108, cancer 80, neuropathy 43. Monoclonal proteins: IgG 407, IgM 78, IgD 2, biclonal 16, triclonal 1; no heavy chain 21, light chain Kappa 389. Variables (mean): monoclonal component: 14 g/l, ESR 32,5, bone marrow: 5,9% plasma cells beta2-microglobulin: 2,59 mg/l, albumin: 3,1g/l, bone survey: normal 39,5%. Evolution: transient MGUS 20 cases. Time to disappearance 2,6 months (1,4-4,6). Evolution to malignant gammopathy 24 cases, time to progression 3 years (IC 1,82-4,3). RESULTS Several factors were associatedç with malignant transformation: heavy chain IgA (p &lt; 0,002), ESR (p &lt; 0,001), age &lt; 70 (p &lt; 0,05), bone marrow percentage of plasma cells (p &lt; 0,002) y ostheoporosis (p &lt; 0,005). A MGUS follow up model is suggested.</dc:description>
<dc:type>English Abstract</dc:type>
<dc:language>es</dc:language>
<dc:date>2008 Jun </dc:date>
<dc:title xml:lang="es">Serie de 618 casos de gammapatías monoclonales de significado indeterminado (GMSI): factores predictivos de desaparición del componente monoclonal o de evolución a gammapatías malignas.</dc:title>
<dc:title xml:lang="en">[A series of 618 cases of monoclonal gammopathies of undetermined significance: predictive factors of disappearance of monoclonal component or evolution to malignant gammopathies].</dc:title>
<dc:publisher>Revista clinica espanola</dc:publisher>
</metadata>
</record>
</pubmed-document>
